Company Overview
Afya Limited operates as a medical education group in Brazil. The company operates in three segments: Undergraduate, Continuing Education, and Medical Practice Solutions. The Undergraduate segment offers educational services through undergraduate courses related to medical school, health sciences, and other non-health undergraduate programs, including medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, biomedicine, business administration, accounting, law, civil and industrial engineering, and pedagogy. The Continuing Education segment provides medical education, including residency preparation programs, specialization test preparation, graduate courses in medicine, and digital and in-person professional development for physicians and medical students. The Medical Practice Solutions segment offers clinical decision support platforms, medical practice management software, healthcare financial services, and digital healthcare ecosystem solutions, such as electronic medical records, practice management tools, telemedicine, digital prescriptions, and doctor-patient relationship platforms. This segment also provides a subscription-based mobile app and website portal that focuses on assisting health professionals and students with clinical decision-making through tools, such as medical calculators, charts, and updated content, as well as prescriptions, clinical scores, medical procedures and laboratory exams, and others. The company also offers educational health and medical imaging; and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools. In addition, it offers printed and digital content, as well as an online medical education platform and physicians, healthcare professionals and students. Afya Limited was founded in 1999 and is headquartered in Belo Horizonte, Brazil.
Why Investors Should Care
Generates a return on equity of 16.7%, reflecting efficient use of shareholder capital.
Net profit has compounded at 26.3% per year over the last five years.
Revenue has grown at a 16.7% CAGR over the past five years.
Trades at a P/E of 8.5, below the sector median of 18.6.
Maintains a net profit margin of 20.4%.
Offers a dividend yield of 4.60%.
Recent Developments
- Dec 2025 Revenue of $3.70B (+11.9% YoY); net profit $752.46M.
- Trailing 12 Months Year-on-year growth — revenue +5.7%, earnings +17.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 16.7%, profit CAGR 26.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 16.65% |
| 1 Year: | 5.70% |
Compounded Profit Growth
| 5 Years: | 26.29% |
| 1 Year: | 17.60% |
Stock Price Performance
| 1 Year: | +0.01% |
| 6 Months: | +6.51% |
| 3 Months: | -1.04% |
| 1 Month: | +2.81% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)50.06 · Neutral
P/E of 8.46 is below the sector median of 18.56 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 20.4%.
- Compounding revenue at 16.7% over 5 years.
- Profit CAGR of 26.3% over 5 years.
- Attractive dividend yield of 4.60%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Defensive).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AFYA Afya Limited | 14.29 | 8.46 | $713.13M | 4.60% | 14.32% | 16.68% | 16.65% | 26.29% |
| 2 | WMT Walmart Inc. SPXR3K | 107.14 | 38.82 | $850.02B | 0.93% | 16.83% | 22.31% | 3.82% | 3.24% |
| 3 | COST Costco Wholesale Corporation NDXSPXR3K | 910.18 | 45.88 | $403.65B | 0.65% | 25.96% | 29.15% | 8.16% | 11.45% |
| 4 | KO The Coca-Cola Company SPXR3K | 88.36 | 26.53 | $380.17B | 2.41% | 16.47% | 42.05% | 2.86% | 4.46% |
| 5 | PG The Procter & Gamble Company SPXR3K | 145.58 | 21.99 | $338.39B | 2.95% | 22.49% | 30.29% | 0.52% | 1.59% |
| 6 | PM Philip Morris International Inc. SPXR3K | 184.73 | 25.37 | $287.92B | 3.09% | 34.03% | -113.55% | -1.69% | 3.57% |
| 7 | PEP PepsiCo, Inc. NDXSPXR3K | 138.45 | 18.15 | $189.12B | 4.43% | 15.41% | 51.51% | 4.93% | 2.11% |
| 8 | BUD Anheuser-Busch InBev SA/NV | 79.73 | 17.18 | $139.30B | 1.69% | 8.49% | 11.39% | 0.88% | 4.63% |
| 9 | BTI British American Tobacco p.l.c. | 55.15 | 14.18 | $118.73B | 5.98% | 12.44% | 13.42% | -2.53% | 5.21% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 936.36M | 919.40M | 928.50M | 912.99M | 1.01B |
| Cost of Revenue | - | 282.64M | 342.71M | 339.92M | 348.63M | 314.65M |
| Gross Profit | - | 653.72M | 576.69M | 588.59M | 564.36M | 698.06M |
| Operating Expenses | - | 281.19M | 291.46M | 311.23M | 285.88M | 304.46M |
| Operating Income | - | 372.53M | 285.23M | 277.36M | 278.48M | 393.60M |
| EBITDA | - | 491.05M | 424.51M | 396.66M | 396.45M | 526.01M |
| Interest Expense | - | 117.47M | 135.81M | 121.36M | 99.74M | 128.72M |
| Pretax Income | - | 281.82M | 194.01M | 180.64M | 204.48M | 304.22M |
| Tax Provision | - | 24.78M | 17.47M | 21.22M | 29.03M | 42.45M |
| Net Income | - | 252.00M | 172.33M | 155.17M | 172.96M | 257.02M |
| Diluted EPS | - | 2.76 | 1.88 | 1.70 | - | 2.85 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 2.33B | 2.88B | 3.30B | 3.70B |
| Cost of Revenue | - | 859.55M | 1.11B | 1.22B | 1.31B |
| Gross Profit | - | 1.47B | 1.77B | 2.09B | 2.38B |
| Operating Expenses | - | 805.58M | 999.04M | 1.08B | 1.17B |
| Operating Income | - | 663.92M | 767.06M | 1.01B | 1.21B |
| EBITDA | - | 923.30M | 1.11B | 1.38B | 1.67B |
| Interest Expense | - | 288.65M | 386.30M | 366.35M | 439.45M |
| Pretax Income | - | 428.43M | 429.58M | 676.39M | 860.95M |
| Tax Provision | - | 35.68M | 24.17M | 27.47M | 92.50M |
| Net Income | - | 373.57M | 386.32M | 631.51M | 752.46M |
| Diluted EPS | - | 4.12 | 4.27 | 6.93 | 8.24 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 7.20B | 7.58B | 8.83B | 9.36B |
| Current Assets | - | 1.64B | 1.20B | 1.59B | 1.94B |
| Cash & Equivalents | - | 1.09B | 553.03M | 911.01M | 1.13B |
| Inventory | 11.83M | 12.19M | 1.38M | - | - |
| Receivables | - | 452.83M | 546.44M | 595.90M | 717.37M |
| Total Liabilities | - | 3.95B | 3.94B | 4.52B | 4.47B |
| Current Liabilities | - | 905.69M | 1.06B | 1.14B | 884.04M |
| Long Term Debt | - | 1.74B | 1.62B | 1.83B | 1.99B |
| Total Debt | - | 2.71B | 2.68B | 3.17B | 3.12B |
| Total Equity | - | 3.20B | 3.60B | 4.27B | 4.85B |
| Shares Outstanding | - | 93.72M | 93.72M | 93.72M | 93.72M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 843.90M | 1.04B | 1.43B | 1.53B |
| Investing Cash Flow | - | -591.47M | -1.14B | -1.09B | -507.07M |
| Financing Cash Flow | - | 92.94M | -439.94M | 23.97M | -808.34M |
| Capital Expenditure | - | -297.02M | -245.43M | -392.62M | -364.01M |
| Free Cash Flow | - | 546.88M | 798.20M | 1.04B | 1.17B |
| Net Change in Cash | - | 345.37M | -539.37M | 365.01M | 216.18M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 63.1% | 61.4% | 63.2% | 64.5% |
| Operating Margin % | - | 28.5% | 26.7% | 30.6% | 32.8% |
| Net Margin % | - | 16.0% | 13.4% | 19.1% | 20.4% |
| ROE % | - | 11.7% | 10.7% | 14.8% | 15.5% |
| ROCE % | - | 10.5% | 11.8% | 13.2% | 14.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 5.45% | 2.61M | $35.55M |
| 2 | Softbank Group Corporation | 5.08% | 2.43M | $33.09M |
| 3 | Doma Perpetual Capital Management LLC | 5.01% | 2.40M | $32.65M |
| 4 | BAMCO Inc. | 2.45% | 1.18M | $16.00M |
| 5 | Renaissance Technologies, LLC | 0.72% | 343.30K | $4.67M |
| 6 | Blackrock Inc. | 0.68% | 323.79K | $4.40M |
| 7 | Swedbank AB | 0.39% | 189.20K | $2.57M |
| 8 | Two Sigma Investments, LP | 0.32% | 155.71K | $2.12M |
| 9 | State Street Corporation | 0.27% | 128.44K | $1.75M |
| 10 | Citadel Advisors Llc | 0.23% | 108.59K | $1.48M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AFYA
New Strong Sell Stocks for September 2nd
AGCO, AFYA and ASEKY have been added to the Zacks Rank #5 (Strong Sell) List on September 2, 2026.
New Strong Sell Stocks for August 26th
AFYA, APTV and CVCO have been added to the Zacks Rank #5 (Strong Sell) List on August 26th, 2026.
Afya Limited Comments on Recent Public Disclosure Made by Yduqs Participações S.A. Regarding a Potential Business Combination
BELO HORIZONTE, Brazil, August 24, 2026--Afya Limited, or "Afya" (Nasdaq: AFYA) announced today that discussions with Yduqs Participações S.A. (B3: YDUQ3) ("Yduqs") regarding a potential business combination involving the two companies are …
Has Afya (NasdaqGS:AFYA) Fallen Far Enough To Look Reasonable?
Afya stock has delivered a decline of nearly 30% over the past five years, yet its current valuation checks and market multiples now point to a company that looks cheap rather than expensive. Afya shares are down 29.9% over the last five ye…
Afya (AFYA) Q2 2026 Earnings Call Transcript
Medical education revenue grew 7% amid AI competition in clinical tools.
Afya Ltd (AFYA) (Q2 2026) Earnings Call Highlights: Solid Growth and Strategic Capital Returns ...
Afya Ltd (AFYA) reports 7% revenue growth in H1 2026, returning 106% of free cash flow to shareholders while navigating margin contraction and regulatory shifts.
AFYA — Frequently Asked Questions
What is the current share price of Afya Limited (AFYA)?
As of 2026-09-19 21:16 PDT, Afya Limited (AFYA) trades at $14.29 on NasdaqGS. Its 52-week range is $12.60 to $15.86.
What is the market capitalisation of AFYA?
Afya Limited (AFYA) has a market capitalisation of $713.13M on NasdaqGS.
What is the P/E ratio of AFYA?
AFYA trades at a trailing price-to-earnings (P/E) ratio of 8.46. The industry average P/E is 18.56. Its price-to-book (P/B) ratio is 1.28.
Does AFYA pay a dividend?
Afya Limited (AFYA) currently offers a dividend yield of 4.60%.
What is the return on equity (ROE) of AFYA?
AFYA has a return on equity (ROE) of 16.68%. Its return on capital employed (ROCE) is 14.32%.
Is AFYA a good stock to buy?
This page provides a data-driven analysis of Afya Limited (AFYA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.